Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1800-1805

  Zhao, Juping ^a   Zhu, Yu ^a   Zhang, Chongyu ^a   Wang, Xiaojing ^a   He, Hongchao ^a   Wang, Haofei ^a   Wu, Yuxuan ^a   Zhou, Wenlong ^a   Shen, Zhoujun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adjuvant therapy; High risk; Renal cell carcinoma; Sorafenib; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

SORAFENIB; SUNITINIB;

ADVANCED CANCER; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CHINESE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NEUTROPENIA; PATIENT SELECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PRURITUS; STOMATITIS; TASTE DISORDER;

ADJUVANT THERAPY; HIGH RISK; RENAL CELL CARCINOMA; SORAFENIB; SUNITINIB; TYROSINE KINASE INHIBITOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DIARRHEA; DISEASE-FREE SURVIVAL; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HAND-FOOT SYNDROME; HUMANS; INDOLES; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84886298776     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.04.019     Document Type: Article

References (18)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2009, 2009:225-249.
2. Jemal A., Siegel R., Xu J., et al. Cancer statistics. CA Cancer J Clin 2010, 2010:277-300.
3. Cohen H.T., McGovern F.J. Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490.
4. Golimbu M., Joshi P., Sperber A., et al. Renal cell carcinoma: Survival and prognostic factors. Urology 1986, 27:291-301.
5. Lam J.S., Shvarts O., Leppert J.T., et al. Renal cell carcinoma 2005: New frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005, 173:1853-1862.
6. Lam J.S., Shvarts O., Leppert J.T., et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005, 174:466-472. Discussion:72; Quiz:801.
7. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
8. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon α in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
9. Choueiri M., Tannir N., Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr. Clin Pharmacol 2011, 6:144-150.
10. Leibovich B.C., Blute M.L., Cheville J.C., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer 2003, 97:1663-1671.
11. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the united states, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
12. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
13. Hutson T.E., Figlin R.A., Kuhn J.G., et al. Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
14. Janzen N.K., Kim H.L., Figlin R.A., et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30:843-852.
15. Jonasch E., Haluska F.G. Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities. Oncologist 2001, 6:34-55.
16. Patard J.J., Rioux-Leclercq N., Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006, 49:633-643.
17. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
18. Négrier S., Ravaud A. Optimization of sunitinib therapy in metastatic renal cell carcinoma: Adverse-event management. EJC Supplements 2007, 5:12-19.